Nextgenediting Template PLOS_One_Word_Template.docx www.nextgenediting.com [double click header to delete] 1 1 6-O-galloylsalidroside, an active ingredient from Acer tegmentosum, ameliorates 2 alcoholic steatosis and liver injury in a mouse model of chronic ethanol 3 consumption 4 5 Young Abstract 23 We previously reported that Acer tegmentosum extract, which is traditionally used to 24 treat liver disease in Korea, may help reduce fat accumulation, improve liver 25 metabolism, and suppress inflammation in alcoholic liver disease. The active 26 ingredient was found to be 6-O-galloylsalidroside, which was isolated from the 27 methanol extract of A. tegmentosum. We hypothesized that 6-O-galloylsalidroside 28 extracted from A. tegmentosum may help protect from liver damage and attenuate 29 hepatic fat accumulation associated with chronic alcohol consumption. In the present 30 study, we aimed to investigate whether 6-O-galloylsalidroside can regulate alcoholic 31 fatty liver and liver injury in mice. For this purpose, mice were fed with Lieber-32 DeCarli 5% ethanol diet for 11 days to induce steatosis and liver injury. Oral 6-O-33 galloylsalidroside was administered once a day for 11 days. Intrahepatic lipid 34 accumulation caused by alcohol consumption was measured using in vivo 1H 35 magnetic resonance imaging. Hepatic steatosis was observed histologically in tissue 36 samples stained with hematoxylin and eosin, as well as Oil Red O. The serum levels 37 of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were 38 measured, as well as the triglyceride content in liver homogenates. On magnetic 39 resonance spectroscopy, 6-O-galloylsalidroside appeared to alleviate alcohol-induced 40 steatosis, which was reflected in decreased hepatic and serum triglyceride levels 41 despite ethanol feeding. Furthermore, 6-O-galloylsalidroside treatment was associated 42 with decreased RNA expression of Cd36, which plays an important role in the 43 development of alcoholic steatosis through the hepatic de novo lipogenesis pathway.
To test this hypothesis, we first established a chronic-plus-binge ethanol feeding 72 model in mouse, characterized by alcohol-induced fat accumulation and immune 73 responses underlying alcoholic liver injury, which leads to alcoholic hepatitis [18] [19] [20] .
74 Furthermore, as the usefulness of in vivo 1H magnetic resonance imaging (1H-MRI) 75 as a nondestructive and noninvasive analytical technique to measure fat levels in 82 Several groups have observed increased hepatic Cd36 expression at the transcriptional 83 and translational levels in alcohol-fed mice. Cd36 is a class B scavenger receptor that 84 may contribute to the lipid metabolism. It is thought that increased Cd36 expression 85 promotes alcoholic steatosis through triglyceride synthesis and de novo lipogenesis in 86 chronic alcohol-fed mice [21, 22] . Therefore, we tested whether any effect of 6-O-87 galloylsalidroside on fat accumulation is mediated by suppression of Cd36 expression 88 in chronic alcohol-fed mice. Body weight and food intake evaluation 148 The body weight and food intake were measured daily between 4 PM and 6 PM. The
149
food intake was calculated based on the measurements on the tube feeding (Bio-Serv,
150
Frenchtown, NJ, USA), which was specifically designed to dispense liquid diets.
152
Evaluation of serum and liver samples 153 On day 11 of the experiment, the animals were anesthetized using isoflurane and 500 154 µL of blood were collected from the orbital sinus. The blood was allowed to clot and 155 then centrifuged at 4000 ×g for 10 min. difference between Ethanol-fed + GAL group and Ethanol-fed group ( Fig. 2A) . Food 11 243 intake was the same in all groups. Furthermore, there were no significant between-244 group differences regarding the liver, kidney, or spleen relative weight (Fig. 2C) .
245
We conducted 1H-MRI-based measurements of proton density fat fraction to confirm 246 the establishment of alcoholic fatty liver. There was no between-group difference in 247 fat liver volume at the beginning of the experiment (i.e., after 4 days during which all 248 mice consumed control Lieber-DeCarli diet). However, at 11 days, the volume of 249 hepatic fat was higher in ethanol-fed mice than in pair-fed controls (Fig. 3A) ,
250
reflected in a three-fold higher fat fraction factor (Fig. 3B) , whereas 6-O-251 galloylsalidroside-treated ethanol-fed mice had a fat fraction factor as low as that of 252 pair-fed controls. The histopathology and Oil Red O staining findings were highly 253 consistent with the 1H-MRI data (Fig. 3C) .
254
Among ethanol-fed mice, significantly lower levels of both serum and hepatic 255 triglycerides were detected in Ethanol-fed + GAL group than in Ethanol-fed group 256 (Fig. 4A, B ). However, no significant between-group differences were observed 257 regarding total cholesterol levels in the serum ( Fig 4B) . 
290
We found that the gene expression of Cd36 was significantly higher in Ethanol-fed 291 group than in Pair-fed group, but this effect was significantly reduced in Ethanol- 
295
Abbreviations: GAL, 6-O-galloylsalidroside ( Fig 5) . 
308
The levels of ALT and AST were significantly higher in Ethanol-fed group than in 309 Pair-fed group. This effect was reduced in ethanol-fed mice treated with 6-O-310 galloylsalidroside. Although the reduction was not statistically significant, the levels 311 of ALT and AST in ethanol-fed mice treated with 6-O-galloylsalidroside were similar 312 to those in pair-fed controls (Fig. 6A ). Immunohistochemistry evaluation revealed no 313 differences in Cyp2e1 expression between Ethanol-fed + GAL group and Ethanol-fed 314 group (Fig. 6B) . 
